Fintel reports that on September 22, 2023, Needham reiterated coverage of Harmony Biosciences Holdings (NASDAQ:HRMY) with a Buy recommendation.
Fintel reports that on September 22, 2023, Needham reiterated coverage of Harmony Biosciences Holdings (NASDAQ:HRMY) with a Buy recommendation.